LB Pharma Q2 net loss $51.6M, cash $327.8M, NOVA-2 readout accelerated to H1 2027

LB PHARMACEUTICALS INC

Q2 2026 net loss $51.6M vs $4.9M; R&D expenses $44.1M vs $2.4M.
Cash and marketable securities $327.8M at 6/30/26, plus $150M July private placement; runway beyond Q2 2029.
Pivotal Phase 3 NOVA-2 topline readout accelerated to H1 2027; pre-NDA meeting planned H2 2027.
Phase 2 bipolar depression (ILLUMINATE-1) data expected Q1 2028; MDD adjunctive trial starts early 2027.
Appointed Christopher Zergebel as SVP Clinical Operations in June 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.